Clinical experience with ertapenem in the treatment of infections of the biliary tract in daily practice in five Spanish hospitals

References

• Johannsen EC, Madoff LC. Infections of the liver and biliary system. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Elsevier Inc.; 2005. p. 951–9.
   Google Scholar
• Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117:632–9.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M, et al.. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:15–26.
   PubMedGoogle Scholar
• Oller Sales B, Rodríguez Conde N. Biliary tract infection: which antibiotics and in which setting [Article in Spanish]. Med Clin (Barc). 2003;121:779–81.
   PubMed Web of Science ®Google Scholar
• Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs. 1999;57:81–91.
   PubMed Web of Science ®Google Scholar
• Bornman PC, van Beljon JI, Krige JE. Management of cholangitis. J Hepatobiliary Pancreat Surg. 2003;10:406–14.
   PubMedGoogle Scholar
• Miura F, Takada T, Kawarada Y, Nimura Y, Wada K, Hirota M, et al.. Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:27–34.
   PubMedGoogle Scholar
• Cantón R, Loza E, Aznar J, Calvo J, Cercenado E, Cisterna R, et al.. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter. 2011;24:223–32.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, et al.. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43:1407–14.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Dubreuil L, Calvet L. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria. Int J Antimicrob Agents. 2006;28:25–35.
   PubMed Web of Science ®Google Scholar
• Betriu C, Salso S, Sáchez A, Culebras E, Gómez M, Rodríguez-Avial I, et al.. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents. 2006;28:1–5.
   PubMed Web of Science ®Google Scholar
• De la Pena A, Asperger W, Köckerling F, Raz R, Kafka R, Warren B, et al.. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg. 2006;10:567–74.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al.. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg. 2003;237:235–45.
   PubMed Web of Science ®Google Scholar
• Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt). 2007;8:15–28.
   PubMedGoogle Scholar
• Navarro NS, Campos MI, Alvarado R, Quintero N, Branicki FJ, Wei J. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg. 2005;3:25–34.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
   PubMedGoogle Scholar
• Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW. Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Crit Care Med. 2003;31:670–5.
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
   PubMed Web of Science ®Google Scholar
• Hirschmann JV. Pyogenic biliary tract and hepatic infections. In: Root RK, Waldvogel F, Corey L, Stamm WE, editors. Clinical infectious diseases, a practical approach. Oxford: Oxford University Press Inc.; 1999. p. 597–603.
   Google Scholar
• Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: ertapenem for complicated intra-abdominal infections. Aliment Pharmacol Ther. 2008;27:919–31.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009;12:234–44.
   PubMed Web of Science ®Google Scholar
• An MM, Zou Z, Shen H, Zhang JD, Chen ML, Liu P, et al.. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2009;9:193.
   PubMed Web of Science ®Google Scholar
• Sirvent JM, Rodríguez JI, Rodríguez I, García-Oria M, Roig J, Bonet A. Randomized, prospective and comparative clinical trial of piperacillin/tazobactam versus ceftriaxone plus ornidazole in the treatment of biliary tract infections [Article in Spanish]. Med Clin (Barc). 2003;121:761–5.
   PubMed Web of Science ®Google Scholar
• Tazuma S, Igarashi Y, Tsuyuguchi T, Ohara H, Inui K, Ohya T; BTI Therapy Research Group. Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator. J Gastroenterol. 2009;44:781–92.
   PubMed Web of Science ®Google Scholar
• Tazuma S, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S; BTI Therapy Research Group. Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: a multicenter trial. Hepatol Res. 2011;41:340–9.
   PubMed Web of Science ®Google Scholar
• Lo CM, Liu CL, Fan ST, Lai EC, Wong J. Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg. 1998;227:461–7.
   PubMed Web of Science ®Google Scholar
• Lai PB, Kwong KH, Leung KL, Kwok SP, Chan AC, Chung SC, et al.. Randomized trial of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Br J Surg. 1998;85:764–7.
   PubMed Web of Science ®Google Scholar
• Lo CM, Fan ST, Liu CL, Lai EC, Wong J. Early decision for conversion of laparoscopic to open cholecystectomy for treatment of acute cholecystitis. Am J Surg. 1997;173:513–7.
   PubMed Web of Science ®Google Scholar
• Sharara AI, El Hajj II, Mroueh M, Kyriacos SB, Abdul-Baki H, Chaar HF, et al.. Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. South Med J. 2011;104:189–94.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Cerrillo M, Poza-Montoro A, Fernandez-Diaz E, Iñurrieta-Romero A, Matesanz-David M. Home treatment of patients with acute cholecystitis. Eur J Intern Med. 2012;23:e10–3.
   PubMed Web of Science ®Google Scholar